{"pmid":32313872,"pmcid":"PMC7164882","title":"COVID-19 convalescent plasma transfusion.","text":["COVID-19 convalescent plasma transfusion.","Hematol Transfus Cell Ther","Langhi, Dante Mario","Santis, Gil Cunha De","Bordin, Jose Orlando","32313872"],"journal":"Hematol Transfus Cell Ther","authors":["Langhi, Dante Mario","Santis, Gil Cunha De","Bordin, Jose Orlando"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313872","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.htct.2020.04.003","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714520128389120,"score":8.518259,"similar":[{"pmid":32319102,"title":"Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.","text":["Points to consider in the preparation and transfusion of COVID-19 convalescent plasma.","This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. The document covers the following important factors to have in mind when considering this treatment: (a) eligibility criteria of convalescent COVID-19 patients to donate whole blood or plasma, (b) pre-screening and pre-donation testing of convalescent COVID-19 donors; (c) criteria for collection of COVID-19 plasma; (d) post-donation treatment of plasma; and (e) it offers recommendations for plasma transfusion.","Vox Sang","Epstein, Jay","Burnouf, Thierry","32319102"],"abstract":["This document prepared and endorsed by the Working Party on Global Blood Safety of the International Society of Blood Transfusion presents elements, as of April 2020, to take into consideration in the preparation and transfusion of COVID-19 convalescent plasma as a possible treatment approach of COVID-19. The document covers the following important factors to have in mind when considering this treatment: (a) eligibility criteria of convalescent COVID-19 patients to donate whole blood or plasma, (b) pre-screening and pre-donation testing of convalescent COVID-19 donors; (c) criteria for collection of COVID-19 plasma; (d) post-donation treatment of plasma; and (e) it offers recommendations for plasma transfusion."],"journal":"Vox Sang","authors":["Epstein, Jay","Burnouf, Thierry"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32319102","week":"202017|Apr 20 - Apr 26","doi":"10.1111/vox.12939","keywords":["covid-19","sars-cov-2","convalescent plasma","coronavirus","preparation","transfusion"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087792160771,"score":111.69311},{"pmid":32305026,"pmcid":"PMC7146649","title":"Challenges of Convalescent Plasma Therapy on COVID-19.","text":["Challenges of Convalescent Plasma Therapy on COVID-19.","J Clin Virol","Zhao, Qian","He, Yong","32305026"],"journal":"J Clin Virol","authors":["Zhao, Qian","He, Yong"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32305026","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jcv.2020.104358","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664632934577995776,"score":82.30472},{"pmid":32113510,"pmcid":"PMC7128218","title":"Convalescent plasma as a potential therapy for COVID-19.","text":["Convalescent plasma as a potential therapy for COVID-19.","Lancet Infect Dis","Chen, Long","Xiong, Jing","Bao, Lei","Shi, Yuan","32113510"],"journal":"Lancet Infect Dis","authors":["Chen, Long","Xiong, Jing","Bao, Lei","Shi, Yuan"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32113510","week":"202010|Mar 02 - Mar 08","doi":"10.1016/S1473-3099(20)30141-9","link_comment_for":"25030060","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664640875069702144,"score":82.30472},{"pmid":32240545,"title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.","text":["Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how.","Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number CODID-19 cases escalate steeply world-wide. Prior findings in various viral respiratory diseases including SARS-CoV related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2 neutralizing Ab titers in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.","Vox Sang","Tiberghien, Pierre","de Lambalerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan","32240545"],"abstract":["Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number CODID-19 cases escalate steeply world-wide. Prior findings in various viral respiratory diseases including SARS-CoV related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2 neutralizing Ab titers in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution may reduce the frequency of patient deterioration, and thereby COVID-19 mortality."],"journal":"Vox Sang","authors":["Tiberghien, Pierre","de Lambalerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240545","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12926","keywords":["covid-19","antibody","convalescent plasma","infectious disease","plasma"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638354191286273,"score":78.419334},{"pmid":32219429,"title":"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.","text":["Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.","JAMA","Roback, John D","Guarner, Jeannette","32219429"],"journal":"JAMA","authors":["Roback, John D","Guarner, Jeannette"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219429","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jama.2020.4940","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638742992781313,"score":78.419334}]}